Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine

Purpose:

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

Criteria:

Inclusion Criteria: - Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant - No more than 3 prior chemotherapy regimens in the metastatic setting - Must have at least one target lesion that is radiographically measurable - Good performance status - No history of or current brain or leptomeningeal disease

NCT ID:

NCT00080262

Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb

Backup Contact:

N/A

Location Contact:

New York, New York
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.